IGC Pharma, Inc. (IGC)

NYSEAMERICAN: IGC · Real-Time Price · USD
0.2900
-0.0100 (-3.33%)
At close: Mar 28, 2025, 4:00 PM
0.2988
+0.0088 (3.03%)
After-hours: Mar 28, 2025, 7:57 PM EST
-3.33%
Market Cap 23.43M
Revenue (ttm) 1.24M
Net Income (ttm) -8.81M
Shares Out 79.69M
EPS (ttm) -0.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 265,700
Open 0.3000
Previous Close 0.3000
Day's Range 0.2900 - 0.3000
52-Week Range 0.2600 - 0.9100
Beta 1.21
Analysts Strong Buy
Price Target 3.88 (+1,237.93%)
Earnings Date Feb 18, 2025

About IGC

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2005
Employees 67
Stock Exchange NYSEAMERICAN
Ticker Symbol IGC
Full Company Profile

Financial Performance

In 2023, IGC Pharma's revenue was $1.35 million, an increase of 47.64% compared to the previous year's $911,000. Losses were -$13.00 million, 13.0% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IGC stock is "Strong Buy." The 12-month stock price forecast is $3.88, which is an increase of 1,237.93% from the latest price.

Price Target
$3.88
(1,237.93% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

- IGC-AD1 Could Offer Safer Alternative to Existing Sleep Medications for Alzheimer's - POTOMAC, MD / ACCESS Newswire / March 26, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Comp...

4 days ago - Accesswire

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the ad...

10 days ago - Accesswire

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

POTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's ...

13 days ago - Accesswire

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

POTOMAC, MARYLAND / ACCESS Newswire / March 12, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Ascendiant Capital Markets has issued a coverage repo...

18 days ago - Accesswire

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

POTOMAC, MD / ACCESS Newswire / March 10, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC) announces that Alliance Global Partners (AGP) has issued an analyst update...

20 days ago - Accesswire

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

POTOMAC, MD / ACCESS Newswire / March 4, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced an advancement in its Artificial Intelligence ("AI") platform with the dev...

26 days ago - Accesswire

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

- New science-backed formulations designed to support cellular health, energy metabolism, and cognitive function - POTOMAC, MD / ACCESS Newswire / February 20, 2025 / IGC Pharma, Inc. (NYSE American:I...

5 weeks ago - Accesswire

IGC Pharma Reports Third Quarter Fiscal 2025 Results

POTOMAC, MARYLAND / ACCESS Newswire / February 18, 2025 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results for the third fiscal quarter of 2025 ended...

5 weeks ago - Accesswire

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

- Product Launch Leverages IGC's State-Of-The-Art Manufacturing Facility To Support Revenue-Generating Brand for Immunity & Energy - POTOMAC, MD / ACCESS Newswire / February 11, 2025 / IGC Pharma, Inc...

6 weeks ago - Accesswire

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

POTOMAC, MD / ACCESS Newswire / January 28, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is proud to announce its selection as one of the top 15 finalists in the PREPARE...

2 months ago - Accesswire

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

POTOMAC, MD / ACCESSWIRE / January 13, 2025 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi will be participating in a fir...

2 months ago - Accesswire

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Innovative use of geofencing technology boosts enrollment at select sites POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced to...

2 months ago - Accesswire

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM...

3 months ago - Accesswire

IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology

IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today an expansion of its clinical research program for IGC-AD1, an investigational treatment for Alzheimer's disease. Bu...

4 months ago - Accesswire

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment.

4 months ago - Business Wire

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline

POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced its financial results and strategic advancements for the second fiscal quar...

4 months ago - Accesswire

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer's and Weight Loss Therapies

POTOMAC, MD / ACCESSWIRE / November 6, 2024 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now a...

5 months ago - Accesswire

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

- Company Expands Phase 2 trial to Canada - POTOMAC, MD / ACCESSWIRE / October 17, 2024 / IGC Pharma, Inc (NYSE American:IGC) ("IGC" or the "Company"), today announced enrollment of patients at the Ba...

5 months ago - Accesswire

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge

POTOMAC, MD / ACCESSWIRE / October 3, 2024 / IGC Pharma, Inc. (NYSE American:IGC) proudly announces that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer...

6 months ago - Accesswire

IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's Treatment.

6 months ago - Business Wire

IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer's Disease.

7 months ago - Business Wire

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease.

7 months ago - Business Wire

IGC Pharma Reports First Quarter Fiscal 2025 Results

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Reports First Quarter Fiscal 2025 Results.

8 months ago - Business Wire

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a "Buy" Recommendation and $3.50 Price Target.

9 months ago - Business Wire

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

POTOMAC, Md.--(BUSINESS WIRE)-- #AD--Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile.

9 months ago - Business Wire